Ozempic is FDA-approved for type 2 diabetes, not weight loss. It was first approved in 2017 as a weekly injection to help adults with type 2 diabetes control their blood sugar, and its approved uses have expanded since then to include cardiovascular and kidney protection in people with diabetes. However, the same active ingredient, semaglutide, is sold under a different brand name, Wegovy, specifically for weight management. The two drugs work the same way in the body, but they’re prescribed, dosed, and covered by insurance differently.
What Ozempic Is Approved For
Ozempic has three FDA-approved uses, and all of them require a type 2 diabetes diagnosis. It’s approved to improve blood sugar control alongside diet and exercise, to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and existing heart disease, and to slow kidney disease progression in adults with type 2 diabetes and chronic kidney disease.
It is not approved for weight loss. That distinction matters for prescribing, insurance coverage, and how your doctor frames the treatment plan.
Why People Lose Weight on It
Semaglutide mimics a hormone your gut naturally releases after eating. This hormone signals your brain to reduce appetite, slows down how quickly food leaves your stomach, and increases feelings of fullness. When you take it as a medication, those effects are amplified and sustained throughout the week.
The appetite suppression happens through several brain pathways at once. The drug activates receptors in a part of the brainstem that detects hunger signals, which in turn reduces the reward you feel from eating. It also shifts the balance in your hypothalamus, the brain’s appetite control center, boosting signals that suppress hunger while dialing down signals that stimulate it. The result is that people on semaglutide simply feel less hungry and eat less food without having to fight cravings as hard.
Because this mechanism works regardless of whether someone has diabetes, doctors noticed significant weight loss in diabetes patients taking Ozempic. That observation drove the development of Wegovy, which is the same drug at a higher dose, specifically tested and approved for weight management.
Ozempic vs. Wegovy
Both are semaglutide. Both are weekly injections. Both are also available in daily pill form. The key differences are the approved uses, the maximum dose, and the packaging.
- Ozempic maxes out at 2 mg per week and is approved only for type 2 diabetes and related cardiovascular and kidney conditions.
- Wegovy goes up to 2.4 mg per week and is approved for weight management in adults and children 12 and older, for a type of fatty liver disease, and for cardiovascular risk reduction in adults with obesity or overweight and heart disease.
Wegovy is the only semaglutide product the FDA has approved for weight loss. If your primary goal is losing weight and you don’t have type 2 diabetes, Wegovy is the version designed for you.
How Well It Works for Blood Sugar
For its intended purpose, Ozempic is effective. In real-world data from nearly 1,800 patients with type 2 diabetes, those starting Ozempic at the 1 mg weekly dose saw an average HbA1c reduction of 1.2 percentage points. Patients who stayed on the medication consistently did even better, with an average drop of 1.4 points. For context, HbA1c reflects your average blood sugar over the past two to three months, and a reduction of that size can be the difference between poorly controlled diabetes and reaching a target range.
Beyond blood sugar, semaglutide has shown a 20% reduction in major cardiovascular events (heart attack, stroke, and cardiovascular death) in a large trial of patients with obesity and established heart disease. That cardiovascular benefit is part of why the drug’s approved uses now extend beyond glucose control alone.
Off-Label Prescribing for Weight Loss
Doctors can legally prescribe any FDA-approved drug for a use other than its official indication. This is called off-label prescribing, and it’s common in medicine. Because Ozempic has been easier to find in pharmacies than Wegovy during periods of shortage, and because it contains the same ingredient, many doctors have prescribed Ozempic off-label for weight loss in patients without diabetes.
This practice is widespread enough that insurers have taken notice. Prior authorization requirements for diabetes-indicated semaglutide prescriptions jumped from under 5% of Medicare beneficiaries to nearly 100% by 2025. That shift likely reflects an effort to verify that patients actually have diabetes before approving coverage, rather than using the diabetes version as a workaround for weight loss.
Insurance Coverage Differences
This is where the diabetes-versus-weight-loss distinction has the most practical impact on your wallet. Most insurance plans, including Medicare and Medicaid in nearly every state, cover semaglutide when it’s prescribed for diabetes. Coverage for the weight loss version is far more limited.
Medicare cannot cover semaglutide for weight loss under current federal law, full stop. Medicaid programs aren’t required to cover weight loss drugs either. As of mid-2024, only 13 states covered GLP-1 medications for weight loss through their fee-for-service Medicaid programs, and some states are pulling back. Pennsylvania eliminated Medicaid coverage of GLP-1s for weight loss starting in January 2026.
Private insurance varies widely. Many commercial plans cover Wegovy, but often with prior authorization, step therapy requirements (trying cheaper options first), or high copays. If you have type 2 diabetes and your doctor prescribes Ozempic for blood sugar control, you’re much more likely to get coverage, even though weight loss will happen as a side effect.
Common Side Effects
Gut-related side effects are the most frequent issue. In a two-year study of semaglutide users, 82% experienced some form of gastrointestinal symptoms compared to 54% on placebo. The most common are nausea, stomach pain, bloating, constipation, diarrhea, and vomiting. These are generally mild to moderate in severity.
The good news is that these effects tend to ease up. Most gastrointestinal symptoms improve after about 20 weeks of use. The standard dosing schedule is designed to minimize this discomfort: you start at the lowest dose (0.25 mg) for four weeks, then step up to 0.5 mg, with further increases as needed up to the 2 mg maximum. Each step gives your body time to adjust before the dose goes higher.
The Bottom Line on Which One You Need
If you have type 2 diabetes, Ozempic is designed for you. It will lower your blood sugar, protect your heart and kidneys, and you’ll likely lose weight as a bonus. If you don’t have diabetes and your primary goal is weight management, the correct product is Wegovy, which is the same drug approved and dosed for that purpose. Using Ozempic off-label for weight loss is possible but comes with insurance hurdles, potential supply issues for people who need it for diabetes, and a lower maximum dose than what’s been tested for optimal weight loss results.